seratrodast has been researched along with 2,3-dinor-6-ketoprostaglandin f1alpha in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, S; Igarashi, T; Kaneko, S; Miyazaki, N; Ohmichi, M; Saitoh, T; Tanaka, H; Teramoto, S | 1 |
1 trial(s) available for seratrodast and 2,3-dinor-6-ketoprostaglandin f1alpha
| Article | Year |
|---|---|
Can urinary eicosanoids be a potential predictive marker of clinical response to thromboxane A2 receptor antagonist in asthmatic patients?
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Anti-Asthmatic Agents; Asthma; Benzoquinones; Creatinine; Eicosanoids; Female; Forced Expiratory Volume; Heptanoic Acids; Humans; Leukotriene E4; Male; Middle Aged; Peak Expiratory Flow Rate; Receptors, Thromboxane; Thromboxane B2 | 1999 |